Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy

Administration of lymphodepletion chemotherapy followed by CD19-specific chimeric antigen receptor (CAR)–modified T cells is a remarkably effective approach to treating patients with relapsed and refractory CD19(+) B-cell malignancies. We treated 7 patients with B-cell acute lymphoblastic leukemia (...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Blood
Autors principals: Gardner, Rebecca, Wu, David, Cherian, Sindhu, Fang, Min, Hanafi, Laïla-Aïcha, Finney, Olivia, Smithers, Hannah, Jensen, Michael C., Riddell, Stanley R., Maloney, David G., Turtle, Cameron J.
Format: Artigo
Idioma:Inglês
Publicat: American Society of Hematology 2016
Matèries:
Clinical Trials and Observations
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4874221/
https://ncbi.nlm.nih.gov/pubmed/26907630
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2015-08-665547
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars